Log in to save to my catalogue

Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4 super(+)CD25 supe...

Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4 super(+)CD25 supe...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1412552491

Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4 super(+)CD25 super(++)Fox p3 super(+) regulatory T-cells in advanced melanoma patients

About this item

Full title

Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4 super(+)CD25 super(++)Fox p3 super(+) regulatory T-cells in advanced melanoma patients

Journal title

Journal of translational medicine, 2013-01, Vol.11 (1), p.135-135

Language

English

Formats

More information

Scope and Contents

Contents

Background: In cancer immunotherapy, dendritic cells (DCs) play a fundamental role in the dialog between innate and adaptive immune response, but several immunosuppressive mechanisms remain to be overcome. For example, a high number of CD4 super(+)CD25 super(++)Fox p3 super(+) regulatory T-cells (Foxp3+Tregs) have been observed in the peripheral bl...

Alternative Titles

Full title

Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4 super(+)CD25 super(++)Fox p3 super(+) regulatory T-cells in advanced melanoma patients

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_1412552491

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1412552491

Other Identifiers

ISSN

1479-5876

E-ISSN

1479-5876

DOI

10.1186/1479-5876-11-135

How to access this item